Abstract:Background: Chemotherapy is currently one of the most common/important treatments for cancers; however the occurrence of multidrug resistance (MDR) impedes the successful application of chemotherapeutic agents. The active efflux of anti-cancer drugs through multi-drug resistance protein 1 (MRP1) remains the dominant mechanism of MDR. However, mechanisms underlying the MRP1 upregulation during tumorigenesis and chemotherapy remain elusive. Methods: MRP1 expression, the efflux probability and viability were measured to evaluate MDR of human lung cancer A549/DDP and H1299 cells. Pharmacological treatment, shRNA-based konckdown and rescue were used to assess the function of JNK (c-Jun N-terminal kinase) and Sp1 (stimulatory phosphatase 1). Chromatin immunoprecipitation and dual-luciferase reporter assay were used to test the direct binding and activation of MRP1 promotor by Sp1. Findings: Pharmacological analysis and JNK knockdown revealed the direct modulation of MRP1 expression and MDR by by the JNK signaling pathway. Furthermore, the transcript factor Sp1 downstream of JNK showed close association with MRP1 expression and MDR. Chromatin immunoprecipitation and luciferase assays revealed the direct binding and activation of MRP1 promoter by Sp1, while Sp1 knockdown decreased MRP1 expression and reversed MDR. Importantly, the MRP1 upregulation and MDR mediated by JNK activation were substantially abolished by Sp1 knockdown in both A549/DDP and H1299 cells. Interpretation: This work demonstrates that Sp1 is a critical transcription factor for MRP1 downstream of JNK and plays a key role in MRP1 upregulation and MDR during tumorigenesis and chemotherapy. Targeting Sp1 expression/activation sheds new light on the clinical chemotherapy treatments of cancers.Funding Statement: This work was supported by the National Natural Science Foundation of China (31400708 and 31670843), the Natural Science Foundation of Heilongjiang Province, China (C200624, C201241, and C201453), the Shaanxi Natural Science Funds for Distinguished Young Scholars of China (2019JC-07), the Key Research and Development Program of Shaanxi Province, China (2017SF-113), and the Fundamental Research Funds for the Central Universities (2017qngz10).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Not required.

Research Progress on Relationship Between Transcription Factor Sp1 and Tumor

Role of post-translational modifications of Sp1 in cancer: state of the art

New Insights into the Role of Endoplasmic Reticulum Stress Signaling Protein XBP1 in Tumor Progression

Sp1 and the ‘hallmarks of cancer’

Transcription Factor Specifidty Protein 1: a New Biomarker for Pancreatic Cancer Therapy

SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer

Correlation of transcription factor Sp1 expression with clinical and pathological characteristics and prognosis of hepatocellular carcinoma

Transcription Factor Sp1 is Essential for Expression of VEGF in Human Hepatocellular Carcinoma Cells

Crosstalk of Sp1 and Stat3 Signaling in Pancreatic Cancer Pathogenesis

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

Secreted Phosphoprotein 1 As a Potential Prognostic and Immunotherapy Biomarker in Multiple Human Cancers

Expression of Transcription Factor Sp1 in Human Pancreatic Ductal Carcinoma and Its Relationship with Prognosis

[Expression of Transcription Factor Sp1 in Human Gastric Cancer Tissue and Its Correlation with Prognosis].

Transcription Factor Sp1 Expression in Gastric Cancer and Its Relationship to Long-Term Prognosis

Altered Expression of Transcription Factor Sp1 Critically Impacts the Angiogenic Phenotype of Human Gastric Cancer

SP1 Expression and the Clinicopathological Features of Tumors: A Meta-Analysis and Bioinformatics Analysis.

Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer

SP1 plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines

The transcription factor Sp1 modulates RNA polymerase III gene transcription by controlling BRF1 and GTF3C2 expression in human cells

Transcription factor Sp1 and resistin